Revolution Medicines Set to Report Phase 3 Trial Results for Pancreatic Cancer Drug
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy RVMD?
Source: Newsfilter
- Clinical Trial Progress: Revolution Medicines is expected to soon announce results from its Phase 3 trial of the experimental drug daraxonrasib for pancreatic cancer, which could become the first targeted treatment for this deadly disease, significantly improving patient survival rates if successful.
- Positive Patient Feedback: Former Republican Senator Ben Sasse reported a 76% reduction in his tumors since starting daraxonrasib, despite experiencing notable side effects, which has garnered widespread attention and could further boost the company's stock price.
- Optimistic Market Expectations: RBC Capital Markets analysts predict that if daraxonrasib demonstrates an overall survival benefit exceeding 13 months, the company's stock could rise by 25% to 40%, indicating strong market confidence in the drug's potential.
- Acquisition Rumors Intensify: With the clinical advancements of daraxonrasib, Revolution Medicines' stock has surged nearly 185% over the past year, making it a prime acquisition target as pharmaceutical companies show keen interest in its research outcomes, potentially impacting future market dynamics.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RVMD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RVMD
Wall Street analysts forecast RVMD stock price to fall
20 Analyst Rating
20 Buy
0 Hold
0 Sell
Strong Buy
Current: 96.220
Low
67.00
Averages
86.00
High
147.00
Current: 96.220
Low
67.00
Averages
86.00
High
147.00
About RVMD
Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Revolution Medicines Set to Report Phase 3 Trial Results for Pancreatic Cancer Drug
- Clinical Trial Progress: Revolution Medicines is expected to soon announce results from its Phase 3 trial of the experimental drug daraxonrasib for pancreatic cancer, which could become the first targeted treatment for this deadly disease, significantly improving patient survival rates if successful.
- Positive Patient Feedback: Former Republican Senator Ben Sasse reported a 76% reduction in his tumors since starting daraxonrasib, despite experiencing notable side effects, which has garnered widespread attention and could further boost the company's stock price.
- Optimistic Market Expectations: RBC Capital Markets analysts predict that if daraxonrasib demonstrates an overall survival benefit exceeding 13 months, the company's stock could rise by 25% to 40%, indicating strong market confidence in the drug's potential.
- Acquisition Rumors Intensify: With the clinical advancements of daraxonrasib, Revolution Medicines' stock has surged nearly 185% over the past year, making it a prime acquisition target as pharmaceutical companies show keen interest in its research outcomes, potentially impacting future market dynamics.
See More
Revolution Medicines Nears Release of Pancreatic Cancer Drug Trial Results
- Clinical Trial Progress: Revolution Medicines is expected to release results from its Phase 3 trial of the experimental drug daraxonrasib this quarter, which could become the first targeted treatment for pancreatic cancer, a disease with only a 13% five-year survival rate, highlighting the drug's potential market demand and significance.
- Positive Patient Response: Former Senator Ben Sasse reported a 76% reduction in his tumors since starting the treatment, despite experiencing significant side effects, providing strong evidence for the drug's efficacy and potentially attracting more patients to clinical trials.
- Market Expectations Rise: RBC Capital Markets analysts predict that if the drug demonstrates an overall survival benefit of more than 13 months, Revolution Medicines' stock could rise by 25% to 40%, indicating strong market anticipation for the drug's success, which may influence the company's financing and acquisition strategies.
- Acquisition Rumors Heat Up: Recently, Revolution Medicines' stock surged amid speculation of a potential acquisition by Merck, with CEO Mark Goldsmith stating that despite frequent external rumors, the company remains focused on its own development, reflecting its attractiveness and potential value in the industry.
See More
Form 144: Revolution Medicines (RVMD.US) Executive Plans to Sell $3.58 Million in Common Stock
Stock Sale Announcement: Revolution Medicines plans to sell 37,450 shares of its common stock on March 25, 2026.
Market Value: The total market value of the shares being sold is approximately $3.58 million.
See More
DAFNA Capital Management Reduces Stake in Biotechnology ETF
- Share Reduction: DAFNA Capital Management sold 34,405 shares of iShares Biotechnology ETF (IBB) in Q4 2025, resulting in a $3.31 million decrease in quarter-end position value, reflecting both trading activities and stock price fluctuations.
- Asset Management Impact: This transaction reduced IBB's share of DAFNA's 13F reportable assets to 2.67%, indicating that IBB is no longer among the fund's top five holdings, which highlights its diminishing significance in the investment portfolio.
- Market Performance: As of February 17, 2026, IBB's price stood at $174.02, marking a 27.2% increase over the past year, with an alpha of 15.84 percentage points compared to the S&P 500, showcasing the ETF's strong performance in the biotechnology sector.
- Investment Strategy: The iShares Biotechnology ETF primarily invests in large, commercial-stage biotech companies and employs a passive investment strategy aimed at efficient index replication and liquidity management, although it remains sensitive to interest rates and investor risk appetite.
See More
DAFNA Capital Management Reduces Stake in iShares Biotechnology ETF
- Stake Reduction Details: According to an SEC filing dated February 17, 2026, DAFNA Capital Management reduced its stake in the iShares Biotechnology ETF by 34,405 shares during Q4 2025, resulting in a $3.31 million decrease in position value, highlighting the impact of market fluctuations on the portfolio.
- Asset Allocation Shift: Following the sale, the iShares Biotechnology ETF now comprises 2.67% of DAFNA Capital's 13F reportable assets, indicating a relative decline in the ETF's significance within the overall investment strategy.
- Top Holdings Overview: As of February 17, 2026, DAFNA's top five holdings include NASDAQ:RVMD at $48.15 million (11.3% of AUM) and NYSEMKT:XBI at $41.03 million (9.7% of AUM), reflecting a continued focus on large-cap biotech firms in its investment approach.
- ETF Performance Analysis: As of February 17, 2026, the iShares Biotechnology ETF was priced at $174.02, up 27.2% over the past year, demonstrating stable performance in the biotech sector, though it remains sensitive to shifts in market risk appetite for growth-oriented healthcare stocks.
See More
RBC Capital Markets Lists 13 Biotechs Likely to Attract Takeover Interest
- Acquisition Potential Analysis: RBC Capital Markets analyst Leonid Timashev highlighted that approximately 85 reports on biotech acquisitions have surfaced since 2021, indicating sustained acquisition interest in the sector, particularly for companies like Revolution Medicines (RVMD), Ascendis Pharma (ASND), and Arrowhead Pharma (ARWR).
- Media Impact Variability: Timashev analyzed M&A commentary from four major publications and found that Betaville's hit rate was only 20%-30%, while others achieved hit rates of 60%-70%, demonstrating significant differences in the accuracy and influence of various media on acquisition news.
- Investment Return Potential: Reports from Bloomberg and the Financial Times showed a median return of 27% over 30 days, with the FT's return soaring to 70% over 90 days, underscoring the profound impact of M&A activities on investor returns in the biotech sector.
- Potential Acquirers List: Timashev also identified Merck (MRK), AbbVie (ABBV), and Bristol Myers Squibb (BMY) as the most likely potential buyers, indicating a rising interest from large pharmaceutical companies in acquiring biotech firms.
See More
Revolution Medicines Set to Report Phase 3 Trial Results for Pancreatic Cancer Drug
- Clinical Trial Progress: Revolution Medicines is expected to soon announce results from its Phase 3 trial of the experimental drug daraxonrasib for pancreatic cancer, which could become the first targeted treatment for this deadly disease, significantly improving patient survival rates if successful.
- Positive Patient Feedback: Former Republican Senator Ben Sasse reported a 76% reduction in his tumors since starting daraxonrasib, despite experiencing notable side effects, which has garnered widespread attention and could further boost the company's stock price.
- Optimistic Market Expectations: RBC Capital Markets analysts predict that if daraxonrasib demonstrates an overall survival benefit exceeding 13 months, the company's stock could rise by 25% to 40%, indicating strong market confidence in the drug's potential.
- Acquisition Rumors Intensify: With the clinical advancements of daraxonrasib, Revolution Medicines' stock has surged nearly 185% over the past year, making it a prime acquisition target as pharmaceutical companies show keen interest in its research outcomes, potentially impacting future market dynamics.
See More
Revolution Medicines Nears Release of Pancreatic Cancer Drug Trial Results
- Clinical Trial Progress: Revolution Medicines is expected to release results from its Phase 3 trial of the experimental drug daraxonrasib this quarter, which could become the first targeted treatment for pancreatic cancer, a disease with only a 13% five-year survival rate, highlighting the drug's potential market demand and significance.
- Positive Patient Response: Former Senator Ben Sasse reported a 76% reduction in his tumors since starting the treatment, despite experiencing significant side effects, providing strong evidence for the drug's efficacy and potentially attracting more patients to clinical trials.
- Market Expectations Rise: RBC Capital Markets analysts predict that if the drug demonstrates an overall survival benefit of more than 13 months, Revolution Medicines' stock could rise by 25% to 40%, indicating strong market anticipation for the drug's success, which may influence the company's financing and acquisition strategies.
- Acquisition Rumors Heat Up: Recently, Revolution Medicines' stock surged amid speculation of a potential acquisition by Merck, with CEO Mark Goldsmith stating that despite frequent external rumors, the company remains focused on its own development, reflecting its attractiveness and potential value in the industry.
See More
Form 144: Revolution Medicines (RVMD.US) Executive Plans to Sell $3.58 Million in Common Stock
Stock Sale Announcement: Revolution Medicines plans to sell 37,450 shares of its common stock on March 25, 2026.
Market Value: The total market value of the shares being sold is approximately $3.58 million.
See More
DAFNA Capital Management Reduces Stake in Biotechnology ETF
- Share Reduction: DAFNA Capital Management sold 34,405 shares of iShares Biotechnology ETF (IBB) in Q4 2025, resulting in a $3.31 million decrease in quarter-end position value, reflecting both trading activities and stock price fluctuations.
- Asset Management Impact: This transaction reduced IBB's share of DAFNA's 13F reportable assets to 2.67%, indicating that IBB is no longer among the fund's top five holdings, which highlights its diminishing significance in the investment portfolio.
- Market Performance: As of February 17, 2026, IBB's price stood at $174.02, marking a 27.2% increase over the past year, with an alpha of 15.84 percentage points compared to the S&P 500, showcasing the ETF's strong performance in the biotechnology sector.
- Investment Strategy: The iShares Biotechnology ETF primarily invests in large, commercial-stage biotech companies and employs a passive investment strategy aimed at efficient index replication and liquidity management, although it remains sensitive to interest rates and investor risk appetite.
See More
DAFNA Capital Management Reduces Stake in iShares Biotechnology ETF
- Stake Reduction Details: According to an SEC filing dated February 17, 2026, DAFNA Capital Management reduced its stake in the iShares Biotechnology ETF by 34,405 shares during Q4 2025, resulting in a $3.31 million decrease in position value, highlighting the impact of market fluctuations on the portfolio.
- Asset Allocation Shift: Following the sale, the iShares Biotechnology ETF now comprises 2.67% of DAFNA Capital's 13F reportable assets, indicating a relative decline in the ETF's significance within the overall investment strategy.
- Top Holdings Overview: As of February 17, 2026, DAFNA's top five holdings include NASDAQ:RVMD at $48.15 million (11.3% of AUM) and NYSEMKT:XBI at $41.03 million (9.7% of AUM), reflecting a continued focus on large-cap biotech firms in its investment approach.
- ETF Performance Analysis: As of February 17, 2026, the iShares Biotechnology ETF was priced at $174.02, up 27.2% over the past year, demonstrating stable performance in the biotech sector, though it remains sensitive to shifts in market risk appetite for growth-oriented healthcare stocks.
See More
RBC Capital Markets Lists 13 Biotechs Likely to Attract Takeover Interest
- Acquisition Potential Analysis: RBC Capital Markets analyst Leonid Timashev highlighted that approximately 85 reports on biotech acquisitions have surfaced since 2021, indicating sustained acquisition interest in the sector, particularly for companies like Revolution Medicines (RVMD), Ascendis Pharma (ASND), and Arrowhead Pharma (ARWR).
- Media Impact Variability: Timashev analyzed M&A commentary from four major publications and found that Betaville's hit rate was only 20%-30%, while others achieved hit rates of 60%-70%, demonstrating significant differences in the accuracy and influence of various media on acquisition news.
- Investment Return Potential: Reports from Bloomberg and the Financial Times showed a median return of 27% over 30 days, with the FT's return soaring to 70% over 90 days, underscoring the profound impact of M&A activities on investor returns in the biotech sector.
- Potential Acquirers List: Timashev also identified Merck (MRK), AbbVie (ABBV), and Bristol Myers Squibb (BMY) as the most likely potential buyers, indicating a rising interest from large pharmaceutical companies in acquiring biotech firms.
See More
